Union Chimique Belge

UCB (Union chimique belge) is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with revenues of €3.3 billion that focuses primarily on R&D, specifically involving medications centered on Epilepsy, Parkinson's, & Crohn's diseases. The Company's efforts are focused on treatments for severe diseases treated by specialists, particularly in the fields of central nervous system (CNS) disorders (including epilepsy), inflammatory disorders (including allergy), and oncology.